866-997-4948(US-Canada Toll Free)

Xenical (Obesity) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 49 Pages


After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Xenical is on patent until 2018 in the US and belongs to a class of drugs known as lipase inhibitors which act on the lipase enzyme to inhibit the absorption of fat in the diet. Dietary fat that is not broken down cannot be absorbed and is eliminated, resulting in a caloric deficit for a positive effect on weight control. Xenical is the only anti-obesity drug approved by the FDA for long-term usage (up to one year) for adults and children age 12 and older.

Scope

  • Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xenical including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xenical for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for obesity.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Xenical performance
  • Obtain sales forecast for Xenical from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 17
4.1 Treatment Overview 17

5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 27

6 Xenical (orlistat) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 32
6.5 Forecast 32

7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 38
7.3 Research Methodology 39
7.4 Forecasting Methodology 39
7.4.1 Percent Drug-Treated Obesity Patients 40
7.4.2 Launch and Patent Expiry Dates 40
7.4.3 General Pricing Assumptions 41
7.4.4 Individual Drug Assumptions 41
7.4.5 Generic Erosion 41
7.5 Physicians, Specialists, and Payers Included in This Study 42
7.6 About the Authors 45
7.6.1 Analysts 45
7.6.2 Therapy Director - CVMD and Infectious Disease 46
7.6.3 Director - Medical Devices 46
7.6.4 Global Head of Healthcare 47
7.7 About GlobalData 48
7.8 Disclaimer 48

List of Table


Table 1: Target Pathways in the Treatment of Obesity 15
Table 2: Symptoms of Obesity 16
Table 3: Treatment Guidelines for Obesity 20
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 21
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 22
Table 6: Bariatric Treatment Attributes 26
Table 7: Leading Drug Treatments for Obesity, 2013 27
Table 8: Marketed Obesity Treatment Devices by Type 28
Table 9: Product Profile - Xenical 30
Table 10: Xenical SWOT Analysis, 2013 32
Table 11: Global Sales Forecasts ($m) for Xenical, 2012-2022 33
Table 12: Key Launch Dates - Xenical 40
Table 13: Key Patent Expiries - Xenical 40

List of Chart


Figure 1: Treatment Algorithm for Obesity 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *